China’s Leading Specialty Pharma Delivers Domestic Alternative for High-End Pharmaceutical Excipients

GUANGZHOU, China, July 26, 2026 -- Guangzhou Hanfang Pharmaceutical Company Limited, a global leader in high-end pharmaceutical lipid excipients, today announces the official global launch of Hanfang USP-grade medium-chain triglycerides (MCT), a landmark achievement ending decades of foreign monopoly in the high-end pharmaceutical excipient sector. Developed with proprietary green manufacturing technology, this domestically produced product meets strict USP standards, addresses critical supply chain vulnerabilities for global pharmaceutical and nutraceutical manufacturers, and is now available for pre-orders worldwide.

Core Technological Breakthroughs & Product Highlights

Hanfang USP-grade MCT leverages the company’s patented integrated green technology combining supercritical CO₂ extraction, membrane separation, and chromatographic separation, replacing traditional solvent-based processes that generate high levels of pollution. First approved for domestic market in 2023, the product has now obtained USP certification, enabling a leap in domestic localization of high-end pharmaceutical lipid excipients from 10% to 90%. This breakthrough eliminates reliance on imported MCT, providing global manufacturers with a stable, cost-effective alternative that meets strict quality and purity requirements for injectable formulations, oral medications, and functional foods.

Global Compliance & Certifications

To meet global market access requirements, Hanfang USP-grade MCT has obtained key international certifications including European Union CEP, US FDA US-DMF, and complies with USP standards. The product adheres to regulatory requirements in North America, Europe, and the Asia-Pacific region, enabling seamless integration into global supply chains for pharmaceutical and nutraceutical applications.

Supply Information & Customization Services

Hanfang USP-grade MCT is now open for global pre-orders through Guangzhou Hanfang Pharmaceutical Company Limited’s official website (http://byshanhanfang.com/) and its authorized global distributors. Full-scale production has commenced, with shipments available to over 30 countries and regions. In addition to standard USP-grade MCT, the company offers customized solutions for pharmaceutical and nutraceutical clients, including tailored purity levels and packaging specifications to meet specific formulation needs.

Authoritative Quotes

"The launch of our USP-grade MCT marks a pivotal step in China’s pharmaceutical industry’s drive for technological self-reliance," said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited and Deputy Director of the National Engineering Research Center. "By replacing imported products with high-quality domestic alternatives, we are helping global partners mitigate supply chain risks while reducing environmental impact through our green manufacturing processes."

Industry Context & Corporate Strategy

According to Grand View Research, the global pharmaceutical lipid excipients market is projected to reach $5.2 billion by 2026, driven by growing demand for reliable, high-quality raw materials in drug development and nutraceutical production. Guangzhou Hanfang Pharmaceutical Company Limited’s launch of USP-grade MCT addresses the industry’s urgent need for stable, cost-effective domestic alternatives, aligning with global trends toward supply chain resilience and sustainable manufacturing.

Future Plans

Looking ahead, Guangzhou Hanfang Pharmaceutical Company Limited will continue to invest in R&D for high-end pharmaceutical lipid excipients, expanding its product portfolio to include more innovative solutions for global clients. The company will also strengthen its global sales and service network, providing localized support to partners across key markets in North America, Europe, and Asia-Pacific.

Company Profile

Guangzhou Hanfang Pharmaceutical Company Limited was founded in 1998 and is a leading state-owned pharmaceutical enterprise under the Guangzhou Pharmaceutical Holdings (GPHL) group. Specializing in high-end pharmaceutical lipid excipients, APIs, health products, and technical services, the company operates the only national engineering research center for traditional Chinese medicine (TCM) process technology and new drug development. It holds over 240 patents, has obtained international certifications including EU CEP and US FDA US-DMF, and serves more than 1,000 clients across over 30 countries. As a national "Little Giant" specialized, sophisticated, unique, and new enterprise and national green factory, the company’s mission is to "Care for Life, Pursue Excellence," contributing to global pharmaceutical supply chain security and technological self-reliance.

Contact Information

Company: Guangzhou Hanfang Pharmaceutical Company Limited
Official Website: http://byshanhanfang.com/

© 2026 Guangzhou Hanfang Pharmaceutical Company Limited. All rights reserved.